Enzymatica publ AB
Enzymatica AB (publ), a life science company, develops and sells medical devices for infection-related diseases. The company's product includes ColdZyme, a mouth spray that protects against the upper respiratory viruses that can cause cold and flu symptoms. It also provides enzyme formulations for skin care. The company was incorporated in 2007 and is headquartered in Lund, Sweden.
Enzymatica publ AB (ENZY) - Total Assets
Latest total assets as of September 2025: Skr149.24 Million SEK
Based on the latest financial reports, Enzymatica publ AB (ENZY) holds total assets worth Skr149.24 Million SEK as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Enzymatica publ AB - Total Assets Trend (2007–2024)
This chart illustrates how Enzymatica publ AB’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Enzymatica publ AB - Asset Composition Analysis
Current Asset Composition (December 2024)
Enzymatica publ AB's total assets of Skr149.24 Million consist of 57.4% current assets and 42.6% non-current assets.
| Asset Category | Amount (SEK) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Skr75.21 Million | 38.5% |
| Accounts Receivable | Skr13.56 Million | 7.0% |
| Inventory | Skr16.71 Million | 8.6% |
| Property, Plant & Equipment | Skr14.40 Million | 7.4% |
| Intangible Assets | Skr2.98 Million | 1.5% |
| Goodwill | Skr63.21 Million | 32.4% |
Asset Composition Trend (2007–2024)
This chart illustrates how Enzymatica publ AB's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Enzymatica publ AB's current assets represent 57.4% of total assets in 2024, an increase from 0.0% in 2007.
- Cash Position: Cash and equivalents constituted 38.5% of total assets in 2024, up from 0.0% in 2007.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 33.0% of total assets, an increase from 24.0% in 2007.
- Asset Diversification: The largest asset category is cash and equivalents at 38.5% of total assets.
Enzymatica publ AB Competitors by Total Assets
Key competitors of Enzymatica publ AB based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF
|
USA | $67.26 Billion |
|
Kamada
NASDAQ:KMDA
|
USA | $378.79 Million |
|
One World Pharma Inc
OTCQB:OWPC
|
USA | $6.62 Million |
|
Dongwha Pharm.Co.Ltd
KO:000020
|
Korea | ₩654.63 Billion |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
China | CN¥27.28 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
|
China | CN¥4.97 Billion |
|
Kotra Industries Bhd
KLSE:0002
|
Malaysia | RM363.90 Million |
Enzymatica publ AB - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Enzymatica publ AB generates 0.23x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Enzymatica publ AB is currently not profitable relative to its asset base.
Enzymatica publ AB - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 5.25 | 6.08 | 1.34 |
| Quick Ratio | 3.91 | 5.49 | 1.15 |
| Cash Ratio | 2.47 | 4.58 | 0.00 |
| Working Capital | Skr56.84 Million | Skr 107.39 Million | Skr 18.19 Million |
Enzymatica publ AB - Advanced Valuation Insights
This section examines the relationship between Enzymatica publ AB's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.20 |
| Latest Market Cap to Assets Ratio | 0.11 |
| Asset Growth Rate (YoY) | 55.0% |
| Total Assets | Skr195.22 Million |
| Market Capitalization | $20.94 Million USD |
Valuation Analysis
Below Book Valuation: The market values Enzymatica publ AB's assets below their book value (0.11 x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Enzymatica publ AB's assets grew by 55.0% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Enzymatica publ AB (2007–2024)
The table below shows the annual total assets of Enzymatica publ AB from 2007 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | Skr195.22 Million | +55.05% |
| 2023-12-31 | Skr125.91 Million | -27.81% |
| 2022-12-31 | Skr174.41 Million | +11.06% |
| 2021-12-31 | Skr157.04 Million | -3.08% |
| 2020-12-31 | Skr162.03 Million | +9.69% |
| 2019-12-31 | Skr147.71 Million | -20.23% |
| 2018-12-31 | Skr185.17 Million | +38.37% |
| 2017-12-31 | Skr133.82 Million | -17.72% |
| 2016-12-31 | Skr162.64 Million | +270.89% |
| 2015-12-31 | Skr43.85 Million | -39.24% |
| 2014-12-31 | Skr72.17 Million | +177.38% |
| 2013-12-31 | Skr26.02 Million | +62.39% |
| 2012-12-31 | Skr16.02 Million | +245.00% |
| 2011-12-31 | Skr4.64 Million | -37.14% |
| 2010-12-31 | Skr7.39 Million | +504.62% |
| 2009-12-31 | Skr1.22 Million | +18.17% |
| 2008-12-31 | Skr1.03 Million | +5.40% |
| 2007-12-31 | Skr981.00K | -- |